Date Title Description PDF
26 Jul 2023 On buy-back programmes The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program.   Download
10 May 2023 On P&L The Company releases the first quarter 2023 financial results presentation Download
10 May 2023 On P&L The Company releases the press release related to the first quarter 2023 financial results Download
25 Apr 2023 On business and financial situation ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) Download
21 Feb 2023 On business and financial situation The Company releases the full year 2022 financial results presentation. Download

Pages

15 / 39
Date Title Description PDF
12 Apr 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 5 April and 11 April 2024 Download
05 Apr 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 28 March and 4 April 2024 Download
02 Apr 2024 On business and financial situation ROVI informs on the FDA’s approval of Risvan® as a treatment for schizophrenia Download
29 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 22 March and 27 March 2024 Download
22 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 15 March and 21 March 2024 Download

Pages

10 / 143
Date Title Description PDF
03 Jul 2012 Información sobre dividendos Download
13 Jun 2012 Convocatorias y Acuerdos de Juntas y Asambleas Generales Download
26 Apr 2012 Información sobre resultados (2) Download
26 Apr 2012 Información sobre resultados Download
26 Apr 2012 Convocatorias y Acuerdos de Juntas y Asambleas Generales Download

Pages

180 / 194